Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis.

1 Voting power varies on certain matters pertaining to the General Department with use of the Fund's resources in that Department. 2 Percentages of total votes (5,041,052) in the General Department ...